Chronic hepatitis C (in combination with interferon alfa-2b or peginterferon alfa-2b) in primary patients not previously treated with interferon alfa-2b or peginterferon alfa-2b; during exacerbations after a course of monotherapy with interferon liquid anavar alfa-2b or peginterferon alfa-2b; in patients refractory to monotherapy with interferon alfa-2b or peginterferon alfa-2b.
Hypersensitivity, pregnancy, lactation, chronic heart failure II6-III art, myocardial infarction, renal insufficiency (creatinine clearance – less than 50 ml / min), severe anemia, liver failure, decompensated cirrhosis, autoimmune diseases (including autoimmune hepatitis), not treatable thyroid disease, severe depression with suicidal intentions, children and Youth age (up to 18 years).
Women of childbearing age (pregnancy is not desirable), decompensated diabetes (with bouts of ketoacidosis); chronic obstructive pulmonary disease, pulmonary embolism, chronic heart failure, thyroid disease (including hyperthyroidism), bleeding disorders, thrombophlebitis, mielodeprescia, hemoglobinopathies (including thalassemia, sickle-cell anemia), depression, suicidal (including history), advanced age.
Side effect On the part of the liquid anavar nervous system: headache, dizziness, weakness, malaise, insomnia, fatigue, depression, irritability, anxiety, emotional lability, nervousness, agitation, aggressive behavior, confusion; rarely – suicidal tendencies, increased smooth muscle tone, tremor, paresthesia, hyperesthesia, hypoesthesia, syncope. Since the cardiovascular system: reduction or increase in blood pressure, or bradi- tachycardia, palpitations, cardiac arrest. From the side of hematopoiesis: hemolytic anemia , leukopenia, neutropenia, granulocytopenia, thrombocytopenia; rarely – aplastic anemia.
The respiratory system: dyspnea, cough, sore throat, shortness of breath, bronchitis, otitis media, sinusitis, rhinitis. From the digestive system: dry mouth, decreased appetite, nausea, vomiting, diarrhea, abdominal pain, constipation , taste perversion, pancreatitis, flatulence, stomatitis, glossitis, bleeding gums, hyperbilirubinemia. from the senses: the defeat of the lacrimal glands, conjunctivitis, blurred vision, violation / hearing loss, ringing in the ears. from the musculoskeletal system: arthralgia, myalgia. From the urogenital system: hot flashes, decreased libido, dysmenorrhea, amenorrhea, menorrhagia, prostatitis. Allergic reactions: skin rash, erythema, urticaria, pyrexia, angioedema, bronchoconstriction, anaphylaxis, photosensitivity, erythema multiforme, Stevens-Johnson syndrome, toxic epidermal necrolysis. Other: hair loss, conjunctivitis, alopecia, disturbance of the structure of hair, dry skin, hypothyroidism, chest pain, thirst, fungal infection, viral infection, flu-like cider, sweating, lymphadenopathy.
possible increased severity of liquid anavar side effects. Treatment: removal of the drug, symptomatic therapy.
Interaction with other medicinal products
Medicinal products containing compounds of magnesium and aluminum, simethicone reduces the bioavailability (AUC decreased by 14%, has no clinical significance).
When combined with interferon alfa-2b or peginterferon alfa-2b – synergistic effect.
Appointment of ribavirin during liquid anavar treatment and / or stavudine phosphorylation accompanied by a decrease, which may lead to viremia and treatment regimens require modification.
Increases concentration of phosphorylated metabolites of purine nucleosides (including didanosine, abacavir) and the associated risk of lactic acidosis .
It has no effect on the enzymatic activity of the liver with the participation of cytochrome P450.
Simultaneous eating a high-fat increases the bioavailability of ribavirin (AUC and C max increased by 70%).
should be considered teratogenic, men and women of reproductive age during treatment and for 7 months after the end of treatment should use effective contraception.
Laboratory tests (complete blood count with leukocyte and platelet count, determination of electrolytes, creatinine, functional liver samples) should be carried out before treatment, at 2 and 4 weeks, and more regularly.
in the treatment of ribavirin maximum reduction in hemoglobin content in most cases is observed after 4-8 weeks from start of treatment. By reducing the hemoglobin is less than 110 mg / mL should be temporarily reduce the dose of ribavirin at 400 mg per day, with a decrease in hemoglobin of less than 100 mg / ml dose should be reduced to 50% of the original. In most cases, the recommended dose modifications provide restoration of hemoglobin levels. By reducing the hemoglobin is less than 85 mg / ml taking the drug should be discontinued.
In acute manifestation giperchuvsvitelnosti liquid anavar (urticaria, angioedema, bronchoconstriction, anaphylaxis) use of the drug should be discontinued immediately. Transient rashes do not serve as grounds for interruption of treatment.
During treatment, those experiencing fatigue, drowsiness or disorientation, should refrain from vehicles and Occupation of driving potentially hazardous activities that require high concentration and psychomotor speed reactions.
In connection with a possible worsening of renal function elderly patients prior to use of the drug is necessary to determine kidney function, in particular creatinine clearance. biomex labs reviews